HyperMed Imaging, Inc. is a pioneering company that is harnessing advanced hyperspectral imaging for medical diagnostics to enhance patient care and clinical outcomes. The company's initial product, OxyVu, has secured FDA 510(k) approval for medical diagnostics, measuring microvasculature perfusion to aid physicians in patient care. Numerous published studies have confirmed OxyVu's clinical utility in evaluating wound healing, diabetic foot ulcers, and amputation planning, indicating strong market potential. Founded in 1997, HyperMed operates in the Health Care and Medical Devices industries.
At the 04 April 2018, the company received a significant $5.04M Venture Round investment, demonstrating investor confidence in its innovative technology and market potential. Although details about the investors are not provided, the substantial investment reflects the recognition of HyperMed's value and the promising opportunities in the clinical diagnostic uses of hyperspectral imaging, which is estimated to be in the multi-billion dollar range.
